Zeshan Rana, MD
Interventional Cardiology · Fredericksburg, VANPI 1124158829
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Silk Road Medical, Inc. at 45.8% of the total. Reporting peaked in 2023 at $7,868 and has fallen 81.9% since, to $1,424 in 2025.
Across 257 payments — averaging $90.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Silk Road Medical, Inc.$11K
- Penumbra, Inc.$4K
- Abbott$2K
- Boston Scientific$2K
- W. L. Gore & Associates, Inc.$828
- Inari Medical, Inc.$735
- plus $2K from 20 others
What the payments were for
- Consulting fees$9,00039%
- Travel & lodging$6,19627%
- Food & beverage$8,00935%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Silk Road Medical, Inc. | 11 | $10,632 |
| Penumbra, Inc. | 20 | $4,388 |
| Abbott | 45 | $2,269 |
| Boston Scientific | 76 | $2,148 |
| W. L. Gore & Associates, Inc. | 22 | $828 |
| Inari Medical, Inc. | 3 | $735 |
| Philips North America LLC | 9 | $355 |
| Medtronic(2 entities) | 7 | $349 |
| Abiomed | 5 | $338 |
| AstraZeneca | 12 | $243 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $163 |
| Johnson & Johnson | 9 | $145 |
| Cardiovascular Systems Inc. | 8 | $114 |
| Edwards Lifesciences | 1 | $90 |
| Chiesi USA, Inc. | 4 | $87 |
| Cardiva Medical, Inc. | 3 | $73 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Endologix LLC | 1 | $34 |
| Novartis | 2 | $32 |
| EKOS Corporation | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
| Atricure, Inc. | 1 | $20 |
| Amgen | 1 | $17 |
| Cook Medical LLC | 1 | $15 |
| Nuwellis, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENROUTE Transcarotid Neuroprotection System$14,566
- ENROUTE Transcarotid Stent$10,566
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$4,000
- Indigo$3,755
- Indigo System$1,783
- Diamondback Peripheral$847
- FLOWTRIEVER CATHETER, S$644
- CT THROMBECTOMY SYSTEM KIT$644
- OPTICROSS$265
- GORE EXCLUDER AAA Endoprosthesis$250
- EXCLUDER AAA Endoprosthesis$240
- SUPERA$219
- COROFLOW$207
- Resolute$190
- ESPRIT$152
- ENHANCE Transcarotid Peripheral Access Kit$143
- ENROUTE .014 Guidewire$143
- (5044) MCOT$102
How this compares
$23,205 in reported general payments places this provider in the 85th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 130 | $166,855 |
| Repatha SureclickEvolocumab | 28 | $31,155 |
| XareltoRivaroxaban | 16 | $26,100 |
| EntrestoSacubitril/Valsartan | 13 | $23,993 |
| BrilintaTicagrelor | 11 | $10,378 |
| Rosuvastatin Calcium | 420 | $6,426 |
| Prasugrel Hcl | 35 | $5,414 |
| Metoprolol Succinate | 291 | $4,768 |
| Atorvastatin Calcium | 357 | $4,024 |
| Colchicine | 18 | $3,204 |
| ClopidogrelClopidogrel Bisulfate | 222 | $2,931 |
| Carvedilol | 357 | $2,181 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 87 | $1,530 |
| Ezetimibe | 42 | $1,444 |
| Amlodipine Besylate | 199 | $1,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $166,855130 claims |
| Johnson & JohnsonXarelto | $145 | $26,10016 claims |
| NovartisEntresto | $32 | $23,99313 claims |
| AstraZenecaBrilinta | $243 | $10,37811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Fredericksburg
- Rajiv TayalFredericksburg$984K
- Thomas MartyakFredericksburg$66K
- Clarence FindleyFredericksburg$19K
- Arijit ChandaFredericksburg$11K
- Deepak TalrejaVirginia Beach$1.5M
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Noah JonesFalls Church$238K
- Michael GenVirginia Beach$207K
- Jeremy BockLeesburg$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.